Research
What makes a prescription valid
A prescription is not paperwork that follows a decision. It is the decision, and federal law describes it in terms of who wrote it rather than what it says.
The federal rule is about the person, not the paper
Federal law sets out when a drug may be dispensed only on a prescription, and the operative words are short. Such a drug shall be dispensed only upon a written prescription of a practitioner licensed by law to administer such drug, or on an oral prescription promptly reduced to writing and filed by the pharmacist.
Two things follow from that phrasing. The authority runs from the practitioner, not from the form. And the words "licensed by law" push the question straight out to state law, because that is where practitioners are licensed.
The statute also names the consequence of getting it wrong. Dispensing a drug contrary to that paragraph is deemed an act that results in the drug being misbranded while held for sale.
That is worth sitting with. A product can be perfectly made and still be misbranded in the eyes of federal law purely because of how it was handed over.
The rule everyone quotes is a controlled-substances rule
The sentence most often quoted in arguments about telehealth prescribing is that a prescription must be issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice.
That language is real, and it is narrower than its reputation. It sits in the federal controlled substances regulations, and by its own terms it governs a prescription for a controlled substance.
The companion rule is equally specific. A prescription for a controlled substance may be issued only by a practitioner authorized to prescribe them by the jurisdiction where that practitioner is licensed. The same rule requires registration with the federal drug enforcement agency, or an exemption from it.
None of the compounds this site covers appears by name anywhere in the federal schedules of controlled substances. That is a statement about names in a published list, not a blanket legal classification, and it does not make those compounds approved, safe or unregulated.
The practical upshot is that the famous federal test is not the test that governs most prescribing in this market. What governs it is state law.
Where the clinician-patient relationship rule actually lives
People reasonably assume there is a single national standard for when a remote visit creates a real clinical relationship. There is not one.
That standard sits in state medical practice acts and the rules of state licensing boards. It varies, and the federal telehealth guidance says as much: the ability to deliver care across state lines varies based on state regulations.
What states are deciding differs too. Some address whether an initial visit may be conducted remotely at all. Some address whether it must be live rather than message-based. Some address what a clinician must document.
So a question like "is an online questionnaire enough to establish a relationship" has no single answer. It has an answer per state, published by that state's board.
What a prescription is supposed to carry
The clearest published list of prescription elements is again the controlled-substances one, and it is a useful reference point even where it does not bind.
It requires the date of issue and signature, the patient's full name and address, the drug name, strength, dosage form and quantity, directions for use, and the practitioner's name, address and registration number.
Outside controlled substances, the required content comes from state pharmacy law rather than that federal rule. The shape is broadly familiar, and the details vary by state.
What that list is good for is reading your own label. A carton with no prescriber name, no patient name, no strength and no directions is not carrying the information a dispensed prescription normally carries, whatever the accompanying paperwork says.
The vial that never enters this system at all
A large share of the peptide market is not a prescribing story. It is a sale.
A vial sold with a research-use-only label is being offered without any prescription, which puts it outside the whole framework above rather than at the edge of it. There is no practitioner, no dispensing, and no pharmacy record.
That is a different transaction from a compounded preparation dispensed against a prescription, even when the substance inside is described with the same name.
Knowing which of the two you are looking at is the first question, because almost every other question has a different answer depending on the answer to that one.
What this means for reading a provider
None of the above tells you whether a specific provider is doing things properly. It does tell you which facts would let you form a view.
Is a licensed prescriber reviewing every request, and licensed where you are? Is a pharmacy dispensing, and is it named? Does the label that arrives carry a prescriber, a patient name, a strength and directions?
Or is the transaction a straight sale of a labeled vial, with no clinician anywhere in it?
Those are observable. A provider either publishes them or leaves you to infer them at checkout, and the difference between those two is itself information.
Key takeaways
- Federal law ties a prescription to a practitioner "licensed by law to administer" the drug, which sends the question to state law.
- Dispensing contrary to that provision is deemed to make the drug misbranded while held for sale.
- The "legitimate medical purpose" test people quote is written for controlled substances.
- No compound covered here appears by name in the federal controlled substance schedules.
- The standard for establishing a clinician-patient relationship sits in state practice acts and varies.
- A research-use-only vial sits outside the prescribing framework altogether, not at its edge.
Frequently asked questions
What does federal law actually require for a prescription?
Federal law says such a drug shall be dispensed only upon a written prescription of a practitioner licensed by law to administer it. An oral prescription also works, if it is promptly reduced to writing and filed by the pharmacist. The authority sits with the practitioner, and the phrase "licensed by law" refers out to state licensing. Dispensing contrary to that paragraph is deemed to result in the drug being misbranded while held for sale.
Does the "legitimate medical purpose" rule apply to peptides?
That rule is written for controlled substances. It says a prescription for a controlled substance, to be effective, must be issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice. None of the compounds covered on this site appears by name in the federal schedules of controlled substances, so that particular federal test is generally not the one in play. Prescribing standards for other drugs come from state law instead.
Is an online questionnaire enough to establish a clinician-patient relationship?
It depends on the state, and there is no single national answer. That standard lives in state medical practice acts and the rules of state licensing boards, and federal telehealth guidance notes that the ability to deliver care across state lines varies by state regulation. Some states address whether a first visit may be remote at all, some whether it must be live rather than message-based, and some what must be documented.
What should appear on a dispensed label?
The clearest published list is the federal one for controlled substances. It requires the date of issue, the patient's full name and address, the drug name, strength, dosage form and quantity, directions for use, and the prescriber's name and address. Outside controlled substances the required content comes from state pharmacy law and varies. Reading your own carton against that list is a quick way to see whether it carries what a dispensed prescription normally carries.
What about a vial sold without any prescription?
A vial sold with a research-use-only label is offered without a prescription, which places the transaction outside the prescribing framework rather than at the margin of it. There is no practitioner, no dispensing step and no pharmacy record. It is a materially different transaction from a compounded preparation dispensed against a prescription, even when the substance is described by the same name.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- United States Code Title 21, Section 353(b)(1), Exemptions and consideration for certain drugs, devices, and biological products, 2024 Main Edition — Office of the Law Revision Counsel, U.S. House of Representatives, January 2025
- Title 21 Code of Federal Regulations section 1306.04, Purpose of issue of prescription — Electronic Code of Federal Regulations, Office of the Federal Register, June 2026
- Title 21 Code of Federal Regulations section 1306.03, Persons entitled to issue prescriptions — Electronic Code of Federal Regulations, Office of the Federal Register, March 1997
- Title 21 Code of Federal Regulations section 1306.05, Manner of issuance of prescriptions — Electronic Code of Federal Regulations, Office of the Federal Register, June 2026
- Title 21 Code of Federal Regulations part 1308, Schedules of Controlled Substances, searched in full for every compound this site covers — Electronic Code of Federal Regulations, Office of the Federal Register, August 2026
- Licensing across state lines — Telehealth.HHS.gov, Health Resources and Services Administration, April 2025